United States Cancer Angiogenesis Inhibitors Market Report 2018

Table of Contents

United States Cancer Angiogenesis Inhibitors Market Report 2018

1 Cancer Angiogenesis Inhibitors Overview

• 1.1 Product Overview and Scope of Cancer Angiogenesis Inhibitors
• 1.2 Classification of Cancer Angiogenesis Inhibitors by Product Category
  • 1.2.1 United States Cancer Angiogenesis Inhibitors Market Size (Sales Volume) Comparison by Type (2013-2025)
  • 1.2.2 United States Cancer Angiogenesis Inhibitors Market Size (Sales Volume) Market Share by Type (Product Category) in 2017
  • 1.2.3 VEGF Targeted Therapy
  • 1.2.4 FGF Targeted Therapies
  • 1.2.5 Oncogene Targeted Therapy
  • 1.2.6 Matrix Degrading & Remodeling Targeted Therapy
  • 1.2.7 Others
• 1.3 United States Cancer Angiogenesis Inhibitors Market by Application/End Users
  • 1.3.1 United States Cancer Angiogenesis Inhibitors Market Size (Consumption) and Market Share Comparison by Application (2013-2025)
  • 1.3.2 Cancer
  • 1.3.3 Interferon Alpha-2α
  • 1.3.4 Ocular Neovascularization
• 1.4 United States Cancer Angiogenesis Inhibitors Market by Region
  • 1.4.1 United States Cancer Angiogenesis Inhibitors Market Size (Value) Comparison by Region (2013-2025)
  • 1.4.2 The West Cancer Angiogenesis Inhibitors Status and Prospect (2013-2025)
  • 1.4.3 Southwest Cancer Angiogenesis Inhibitors Status and Prospect (2013-2025)
  • 1.4.4 The Middle Atlantic Cancer Angiogenesis Inhibitors Status and Prospect (2013-2025)
  • 1.4.5 New England Cancer Angiogenesis Inhibitors Status and Prospect (2013-2025)
  • 1.4.6 The South Cancer Angiogenesis Inhibitors Status and Prospect (2013-2025)
  • 1.4.7 The Midwest Cancer Angiogenesis Inhibitors Status and Prospect (2013-2025)
• 1.5 United States Market Size (Value and Volume) of Cancer Angiogenesis Inhibitors (2013-2025)
  • 1.5.1 United States Cancer Angiogenesis Inhibitors Sales and Growth Rate (2013-2025)
  • 1.5.2 United States Cancer Angiogenesis Inhibitors Revenue and Growth Rate (2013-2025)

2 United States Cancer Angiogenesis Inhibitors Market Competition by Players/Suppliers

• 2.1 United States Cancer Angiogenesis Inhibitors Sales and Market Share of Key Players/Suppliers (2013-2018)
• 2.2 United States Cancer Angiogenesis Inhibitors Revenue and Share by Players/Suppliers (2013-2018)
• 2.3 United States Cancer Angiogenesis Inhibitors Average Price by Players/Suppliers (2013-2018)
• 2.4 United States Cancer Angiogenesis Inhibitors Market Competitive Situation and Trends
  • 2.4.1 United States Cancer Angiogenesis Inhibitors Market Concentration Rate
  • 2.4.2 United States Cancer Angiogenesis Inhibitors Market Share of Top 3 and Top 5 Players/Suppliers
  • 2.4.3 Mergers & Acquisitions, Expansion in United States Market
• 2.5 United States Players/Suppliers Cancer Angiogenesis Inhibitors Manufacturing Base Distribution, Sales Area, Product Type

3 United States Cancer Angiogenesis Inhibitors Sales (Volume) and Revenue (Value) by Region (2013-2018)

• 3.1 United States Cancer Angiogenesis Inhibitors Sales and Market Share by Region (2013-2018)
• 3.2 United States Cancer Angiogenesis Inhibitors Revenue and Market Share by Region (2013-2018)
• 3.3 United States Cancer Angiogenesis Inhibitors Price by Region (2013-2018)

4 United States Cancer Angiogenesis Inhibitors Sales (Volume) and Revenue (Value) by Type (Product Category) (2013-2018)

• 4.1 United States Cancer Angiogenesis Inhibitors Sales and Market Share by Type (Product Category) (2013-2018)
• 4.2 United States Cancer Angiogenesis Inhibitors Revenue and Market Share by Type (2013-2018)
• 4.3 United States Cancer Angiogenesis Inhibitors Price by Type (2013-2018)
• 4.4 United States Cancer Angiogenesis Inhibitors Sales Growth Rate by Type (2013-2018)

5 United States Cancer Angiogenesis Inhibitors Sales (Volume) by Application (2013-2018)

• 5.1 United States Cancer Angiogenesis Inhibitors Sales and Market Share by Application (2013-2018)
• 5.2 United States Cancer Angiogenesis Inhibitors Sales Growth Rate by Application (2013-2018)
• 5.3 Market Drivers and Opportunities

6 United States Cancer Angiogenesis Inhibitors Players/Suppliers Profiles and Sales Data

• 6.1 Intas Pharmaceuticals
  • 6.1.1 Company Basic Information, Manufacturing Base and Competitors
  • 6.1.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.1.2.1 Product A
    • 6.1.2.2 Product B
  • 6.1.3 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.1.4 Main Business/Business Overview
• 6.2 Kyowa Hakko Kirin
  • 6.2.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.2.2.1 Product A
    • 6.2.2.2 Product B
  • 6.2.3 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.2.4 Main Business/Business Overview
• 6.3 Levolta Pharmaceuticals
  • 6.3.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.3.2.1 Product A
    • 6.3.2.2 Product B
  • 6.3.3 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.3.4 Main Business/Business Overview
• 6.4 Mabtech
  • 6.4.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.4.2.1 Product A
    • 6.4.2.2 Product B
  • 6.4.3 Mabtech Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.4.4 Main Business/Business Overview
• 6.5 Marsala Biotech
  • 6.5.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.5.2.1 Product A
    • 6.5.2.2 Product B
  • 6.5.3 Marsala Biotech Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.5.4 Main Business/Business Overview
• 6.6 Neumedicines
  • 6.6.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.6.2.1 Product A
    • 6.6.2.2 Product B
  • 6.6.3 Neumedicines Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.6.4 Main Business/Business Overview
• 6.7 Genentech
  • 6.7.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.7.2.1 Product A
    • 6.7.2.2 Product B
  • 6.7.3 Genentech Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.7.4 Main Business/Business Overview
• 6.8 Five Prime Therapeutics
  • 6.8.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.8.2.1 Product A
    • 6.8.2.2 Product B
  • 6.8.3 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.8.4 Main Business/Business Overview
• 6.9 Fuji Film Kyowa Kirin Biologics
  • 6.9.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.9.2.1 Product A
    • 6.9.2.2 Product B
  • 6.9.3 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.9.4 Main Business/Business Overview
• 6.10 Genexine
  • 6.10.2 Cancer Angiogenesis Inhibitors Product Category, Application and Specification
    • 6.10.2.1 Product A
    • 6.10.2.2 Product B
  • 6.10.3 Genexine Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2013-2018)
  • 6.10.4 Main Business/Business Overview
• 6.11 Hetero Drugs
• 6.12 ImClone Systems
• 6.13 Novartis

7 Cancer Angiogenesis Inhibitors Manufacturing Cost Analysis

• 7.1 Cancer Angiogenesis Inhibitors Key Raw Materials Analysis
  • 7.1.1 Key Raw Materials
  • 7.1.2 Price Trend of Key Raw Materials
  • 7.1.3 Key Suppliers of Raw Materials
  • 7.1.4 Market Concentration Rate of Raw Materials
• 7.2 Proportion of Manufacturing Cost Structure
  • 7.2.1 Raw Materials
  • 7.2.2 Labor Cost
  • 7.2.3 Manufacturing Expenses
• 7.3 Manufacturing Process Analysis of Cancer Angiogenesis Inhibitors

8 Industrial Chain, Sourcing Strategy and Downstream Buyers

• 8.1 Cancer Angiogenesis Inhibitors Industrial Chain Analysis
• 8.2 Upstream Raw Materials Sourcing
• 8.3 Raw Materials Sources of Cancer Angiogenesis Inhibitors Major Manufacturers in 2017
• 8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders

• 9.1 Marketing Channel
  • 9.1.1 Direct Marketing
  • 9.1.2 Indirect Marketing
  • 9.1.3 Marketing Channel Development Trend
• 9.2 Market Positioning
  • 9.2.1 Pricing Strategy
  • 9.2.2 Brand Strategy
  • 9.2.3 Target Client
• 9.3 Distributors/Traders List

10 Market Effect Factors Analysis

• 10.1 Technology Progress/Risk
  • 10.1.1 Substitutes Threat
  • 10.1.2 Technology Progress in Related Industry
• 10.2 Consumer Needs/Customer Preference Change
• 10.3 Economic/Political Environmental Change

11 United States Cancer Angiogenesis Inhibitors Market Size (Value and Volume) Forecast (2018-2025)

• 11.1 United States Cancer Angiogenesis Inhibitors Sales Volume, Revenue Forecast (2018-2025)
• 11.2 United States Cancer Angiogenesis Inhibitors Sales Volume Forecast by Type (2018-2025)
• 11.3 United States Cancer Angiogenesis Inhibitors Sales Volume Forecast by Application (2018-2025)
• 11.4 United States Cancer Angiogenesis Inhibitors Sales Volume Forecast by Region (2018-2025)

12 Research Findings and Conclusion

13 Appendix

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources